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266a Monday, February 4, 2013PD increases hERG1 current by multiple effects, including a shift of inactiva-
tion to a more positive voltage, slowing of deactivation and an increase in sin-
gle channel open probability. The efficacy of PD was increased in proportion to
the WT:L646E subunit ratio. The Hill coefficient was 1.40 - 1.55 for all the het-
eromeric concatamers, suggesting a weak positive cooperativity for PD bind-
ing. At a fully effective concentration of PD (10mM), each WT binding site
contributes ~20% towards the maximum response of 80% enhancement of
current.
ICA increases hERG1 current by a profound attenuation of inactivation. An in-
crease in the WT:F557L subunit ratio enhanced the agonist activity of ICA
(10mM and 30mM) in a synergistic fashion. For 2WT/2F557L concatenated
channels, synergy required adjacent (as opposed to diagonal) WT subunits.
In summary, four intact binding sites per channel are required to fully activate
hERG1 by PD or ICA.
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Human ether-a-go-go related gene (hERG) channel inhibitors can be trapped in
the channels at rest. The structural peculiarities of hERG blockers that enable
trapping or alternatively resting state dissociation are currently unknown. Prop-
afenone (small molecule, MW 341 g/mol) is efficiently trapped in the closed
hERG channel pore (1). To investigate whether the size of the blocking mole-
cule plays a role in trapping we synthesized bulky propafenone derivatives con-
taining benzoyl and trimethylphenyl side chains, attached by piperazine linkers,
with molecular weights of 500 (Fba212) and 650 g/mol (Fba213) respectively.
hERG channels were expressed in Xenopus laevis oocyte and potassium cur-
rent inhibition was studied using the two - microelectrode voltage clamp
technique.
It was found: first, both compounds are potent hERG blockers with IC50 3.7mM
(Fba212) and 52mM (Fba213). Secondly, channel block by Fba212 and 213 was
prevented by mutations Y652A and F656A as previously shown for propafe-
none. Third, both propafenone derivatives were trapped at rest. To obtain
insights into the molecular mechanism of channel block docking experiments
with Fba212 and Fba213 in closed and open conformation were performed.
Both compounds interact with the propafenone binding site (Y652A and
F656A). Fba213 was found to exceed the size of the closed channel cavity of
our hERG homology model. We conclude that drug trapping in hERG channels
does not necessarily require full closure of the activation gate.
1. Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC,
Mitcheson JS.
Mol Pharmacol. 2004 Nov; 66(5):1201-12.
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ICA105574 (3-Nitro-N-(4-phenoxyphenyl)-benzamide) activates hERG1
(Kv11.1) channels by reducing inactivation, but inhibits hEAG1 (Kv10.1)
channels by inducing inactivation. using chimeric ERG-EAG constructs, we
found that the channel-specific response to ICA105574 is mediated by the
pore region (S5-pore helix-S6). Simulated docking of ICA105574 on a molec-
ular model of hEAG1 coupled with alanine mutagenesis indicates that similar
to hERG1, ICA105574 binds to a hydrophobic region confined by the S5/S6/
pore helix of one subunit and S6 of adjacent subunit in hEAG1 channels. Based
on the putative ICA binding site and protein sequence alignment, a triple
mutant of hEAG1 (M431F/M458L/L463M hEAG1) was designed to make
the ICA binding region in hEAG1 homologous to hERG1. ICA inhibited the
triple mutant similar to WT-hEAG1, indicating that the amino acid differences
within the putative ICA binding region do not determine the reciprocal func-
tional response to ICA. A single mutation in S5 (F557L), pore helix (L622C)
or S6 (Y652A) of hERG1 eliminates the activity of ICA on hERG1 (Garg, et
al 2011, Mol. Pharm.). The equivalent mutations in hEAG1 affect inactivation
differentially and result in very different responses to ICA. First, Y464A in-
duced inactivation of hEAG1 channels and this gating was accentuated by
ICA. Second, ICA is a partial agonist of F359L and L434C mutant channels.
We recently proposed a tripartite model of slow inactivation for hEAG1 that
involves interaction of the same three residues. We conclude that ICA bindsto the same site in hEAG1 and hERG1 channels, and that the functional conse-
quences are determined by the underlying (fast or slow) mode of selectivity-
filter mediated inactivation.
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The human ether-a-go-go related gene 1 (hERG1) potassium ion channel is
a key element for the cardiac delayed rectified potassium current IKr and it
plays an important role in the normal repolarization of the action potential.
Diverse types of organic compounds used both in common cardiac and noncar-
diac medications can reduce the IKr and may lead to ventricular arrhythmia.
Therefore, several approved drugs have been withdrawn from the market
because of their effects on QT interval prolongation. Since most of these drugs
have high potency for their principal targets, ‘‘rehabilitation’’ studies for de-
creasing their high hERG1 blocking affinities while keeping them active at
the binding site of their targets may lead re-use of these drugs. For this aim,
a gastroprokinetic agent, cisapride, is studied. Cisapride is withdrawn from
the market because of its high hERG1 blocking affinity. In this study, analyses
of fragment interactions of cisapride at the human A2A adenosine receptor and
hERG1 central cavities is investigated using in silico applications (molecular
docking, molecular dynamics simulations, de novo drug design) and novel
and safer (with low hERG1 blocking affinities) of cisapride derivatives are pro-
posed for their synthesis and their biological tests.
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The human Ether-a-go-go Related Gene (hERG) encodes Kv11.1 and underlies
the rapidly activating delayed rectifier Kþ current in the heart, and loss-of-
function hERG mutations cause the type 2 long QT syndrome (LQT2). The
majority of LQT2-linked missense mutations decrease the trafficking of
Kv11.1. An important finding is drugs that bind to Kv11.1 and block current
(IKv11.1) can correct the trafficking for most of these mutations (pharmacolog-
ical correction). We tested the hypothesis that pharmacological correction in-
creases the trafficking of mutant LQT2 channels from the Endoplasmic
Reticulum (ER). Voltage-clamping and Western blotting experiments of
HEK293 cells expressing the trafficking-deficient LQT2 mutation G601S
showed that pharmacological correction still occurred in cells treated with the
protein synthesis inhibitor cycloheximide. Confocal analyses of HEK293 cells
stably expressing wild type Kv11.1 or G601S showed that G601S is selectively
stored in an intermediate ER compartment with BAP31. The intermediate
BAP31 compartment does not overlap with the perinuclear ER compartment,
transitional ER compartment, or the ER Golgi Intermediate Compartment.
Treating cells in E-4031, a drug that corrects G601S trafficking, decreased
G601S co-localization with intermediate BAP31 compartment and increased
G601S immunostaining at the cell surface membrane. Additional experiments
showed that treating cell in E-4031 for as little as 30 min was sufficient to
caused the pharmacological correction of IKv11.1 for many hours. Together
these data demonstrate that a steady-state subpopulation of LQT2 channels is
stored separately in the BAP31 transitional ER compartment and their func-
tional expression is readily corrected by E-4031 treatment.
1370-Pos Board B262
LQT2 Nonsense Mutations Generate Trafficking Deficient N-Terminally
Truncated Channels by the Reinitiation of Translation
Matthew Stump, Qiuming Gong, Zhengfeng Zhou.
OHSU, Portland, OR, USA.
Long QT syndrome type 2 (LQT2) is caused by mutations in the human ether-
a-go-go related gene (hERG). The reinitiation of translation has recently been
reported as a novel pathogenic mechanism of LQT2 by which early PTC mu-
tations generate N-terminally truncated channels with altered gating properties.
We have previously shown that hERG transcripts containing the Q81X muta-
tion were translated at the downstreamM124 codon following premature termi-
nation and generated channels that exhibited increased deactivation kinetics
and decreased resurgent outward current during action potential repolarization.
We have now identified two additional LQT2 nonsense mutations C39X and
C44X that escape nonsense mediated mRNA decay by the reinitiation of trans-
lation. Unlike the Q81X channels, which are expressed at the cell surface,
Monday, February 4, 2013 267aC39X and C44X channel proteins are trafficking defective. We show that C39X
and C44X channels undergo translation reinitiation at M60 which deletes the
hERG N-terminus including the first 34 residues of the Per, Arnt, and Sim
(PAS) domain. In contrast to the reinitiation of Q81X channels at M124, in
which the PAS domain is nearly completely deleted, reinitiation at M60 dis-
rupts the folding of this highly structured domain, precluding the efficient fold-
ing and trafficking of the mutant channels. The RNase protection assay, western
blot analysis and electrophysiology were used to characterize the LQT2 mu-
tants at the RNA, protein, and functional level. Our findings indicate that trans-
lation reinitiation may give rise to trafficking as well as functional defects of
mutant hERG channels associated with LQT2 nonsense mutations.
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The KCNH2 gene encodes a Kþ channel important to normal cardiac electro-
physiology. Its significance is underscored by its link to both hereditary (locus
LQT2) and acquired Long-QT cardiac arrhythmias. Over 400 deleterious mu-
tations have been reported throughout the KCNH2 length. Why the channel is
so susceptible to missense mutations is unclear. More than 50% of LQT2 mu-
tations result in defective assembly and trafficking. There is evidence that even
wild type channels are processed inefficiently. It has also been reported that the
channel protein may reach the surface via atypical pathways. Most attention has
logically focused on the protein for these processes.
Much less is known about mRNA-dependent factors in channel processing. We
analyzed the coding mRNA sequence of KCNH2. It has 66%GC content and 60
potential hair-pin loop segments. We re-synthesized the cDNA to achieve 50%
GC-content and reduce the number of potential hair-pin loops whilemaintaining
identical amino acid coding. Cellular expression of the codon-modified cDNA
(CM-KCNH2) produced ionic currents comparable to native cDNA. Channel
protein was expressed in a dramatically different pattern. Whereas the native
protein (NT-KCNH2) is usually more abundant (immature form) in ER/Golgi
compartments than on the surface, CM-KCNH2 showed a preponderance of
the mature form, indicating channels at the surface. Immunofluorescence analy-
sis confirmed this localization. From these results we hypothesize that KCNH2
translation efficiency, determined by RNA sequence-specific elements indepen-
dent of coding, affect downstream protein assembly and/or trafficking_an
unusual occurrence. As a corollary to this, we postulate a synergy between the
inherently inefficient biosynthesis of KCNH2 and LQT2mutations that contrib-
ute to the pathogenesis of hereditary LQT2. Further investigation ofmechanisms
underlyingmRNA-dependent processing of KCNH2 channelsmay lead us to re-
consider approaches to hereditary and acquired arrhythmia syndromes.
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Reduction of the current carried by the cardiac potassium channel HERG can
lead to Long QT syndrome, an arrhythmia characterized by a rapid heart rate
and reduced cardiac output, which can, in certain situations, be fatal. The effect
of extracellular electrolytes on the biophysical properties of the HERG channel
have been studied in some detail. In particular, increases in extracellular cal-
cium, magnesium and hydrogen have been shown to slow channel activation,
increase channel deactivation, and shift the G-V curve to more positive volt-
ages. A number of reports have also shown that hydrogen can reduce HERG
current by a mechanism that does not involve an effect on channel deactivation
and which likely involves pore block. We show here that reducing extracellular
potassium results in a significant increase in HERG current reduction by extra-
cellular calcium, hydrogen, and magnesium. Current reduction by calcium ap-
pears to be significantly greater than current reduction by magnesium.
Furthermore, the reduction in HERG current by extracellular hydrogen de-
pended on the extracellular calcium concentration. The Drosophila voltage-
gated potassium channel Shaker, showed a much smaller decrease in current
by extracellular calcium and this effect was not dependent on extracellular
potassium. In addition there was no difference in current reduction by calcium
between WT HERG and the inactivation deficient mutant S631A, either in low
or high extracellular potassium. These results suggest that calcium, hydrogen,
and magnesium can block the HERG potassium channel and that calcium, hy-
drogen, magnesium, and potassium may interact at the outer pore of the HERG
channel.1373-Pos Board B265
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KCNE1 and KCNE2 are both expressed in human heart and can associate with
KCNQ1. KCNE1 and KCNE2 share transmembrane topology and sequence ho-
mology, yet they differ in KCNQ1 modulation (KCNE1 slows KCNQ1 Closed-
to-Open transition, while KCNE2 slows KCNQ1 Open-to-Closed transition)
and pharmacology (KCNQ1/KCNE2 is 5 and 10 fold less sensitive than
KCNQ1/KCNE1 to niflumic acid, IKs activator, and azimilide, IKs suppressor).
Previous work has shown that the extracellular juxtamembrane (EJM) region of
KCNE1 interacts with the extracellular surface of KCNQ1 to modulate gating
kinetics and to form IKs activator binding sites. This prompts us to compare the
EJMs of the two KCNE subunits in terms of KCNQ1 interaction. We apply cys-
teine (Cys) scanning mutagenesis to EJMs of KCNE1 and KCNE2 and analyze
the patterns of functional perturbation when coexpressed with KCNQ1. We use
methanethiosulfonate (MTS) reagents to probe the relationship between EJMs
of KCNE subunits and KCNQ1. Finally we probe disulfide formation between
Cys engineered into the EJMs of KCNE subunits and those engineered into ex-
tracellular surface of KCNQ1. The EJM of KCNE1 makes frequent contacts
with KCNQ1, so that MTS modification of exposed Cys side chains can affect
channel gating. KCNQ1/KCNE2 is largely indifferent to MTS modification of
exposed Cys side chains engineered to EJM of KCNE2. However, MTS can
slowly access 7 consecutive hydrophobic positions in the beginning of
KCNE2 transmembrane domain, as if there is a crevice between KCNQ1 and
KCNE2. Disulfide trapping experiments suggest that KCNE2 is leaning more
toward KCNQ1 S2 than KCNE1. We propose that KCNE2 interferes with
S2-S4 interactions during KCNQ1 Open-to-Closed transition and thus slows
deactivation. This weakens sensitivity to niflumic acid and azimilide by affect-
ing binding site directly or by an allosteric mechanism.
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Background: Ion channels composed of a (pore-forming) and b (auxiliary)
subunits use an ‘early-assembly’ strategy (Kir6.x/SUR assembly in ER) to con-
trol cell surface expression, or a ‘late-assembly’ strategy (a/b2 of rat brain Nav
channels, both subunits independently traffic to cell surface) to allow dynamic
control of current amplitude/gating kinetics. Slow delayed rectifier (IKs) chan-
nel is composed of KCNQ1 (Q1, a) and KCNE1 (E1, b) subunits, and functions
as ‘repolarization-reserve’ in human heart. It is not clear which of the 2 assem-
bly strategies Q1 and E1 use in forming IKs.Methods:We express Q1 and E1
tagged with fluorescent-protein (Q1-GFP and E1-dsR) or extracellular epitope
(AU5-Q1 and HA-E1) in COS-7 and neonatal rat ventricular myocytes
(NRVM), and use confocal imaging to track Q1 & E1 movements in cells.
Results: InCOS-7 cells 3 hr after transfection,Q1 andE1 travel in separate trans-
port intermediates without mixing/fusion. E1 reaches the cell surface before Q1.
By 24 hr, Q1 and E1 are colocalized on cell surface. Brefeldin-A (blocking pro-
tein export from ER) prevents surface expression of Q1-147C/E1-40C and re-
duces disulfide formation between the two (as a measure of functional Q1/E1
assembly). In NRVM during in vitro development, Q1-GFP and E1-dsR travel
in distinctly different transport intermediates. As NRVM develops into
mature-like phenotype, Q1-GFP and E1-dsR are colocalized on the cell surface,
with a separate cytosolic Q1-GFP pool colocalized with a-actinin and calnexin
(z-line and ER/SRmarkers, respectively).Conclusions:Q1 andE1 use the ‘late-
assembly’ strategy to afford dynamic control of IKs current amplitude. This ex-
plains why native Q1 and E1 in adult ventricular myocytes are often not well-
colocalized. We propose that cardiac myocytes regulate IKs amplitude dynami-
cally by adjusting the degree of Q1/E1 colocalization on cell surface.
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Long QT syndrome is associated with prolongation of the corrected QT interval
(QTc) and increased risk for ventricular arrhythmias. LQT1 is caused by loss-
of-function mutations in the KCNQ1-encoded Kv7.1 a-subunit which mediates
the slowly activating delayed rectifier Kþ current (IKs) in the heart. A family
with a KCNQ1 missense mutation (I235N) in the voltage-sensor of Kv7.1 has
